CancerVax Corporation Announces Results Of Phase 3 Clinical Trials Of Canvaxin(TM) In Patients With Stage III And Stage IV Melanoma

CancerVax Corporation (NASDAQ: CNVX) announced that data from its Phase 3 clinical trials of Canvaxin™ in the treatment of patients with advanced-stage melanoma will be presented today at the Society for Surgical Oncology's Annual Meeting in San Diego, California.

Back to news